Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Østergaard, SD, Foldager, L, Mors, O, Bech, P & Correll, CU 2018, 'The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia' Acta Psychiatrica Scandinavica, bind 138, nr. 5, s. 420-431. https://doi.org/10.1111/acps.12952

APA

Østergaard, S. D., Foldager, L., Mors, O., Bech, P., & Correll, C. U. (2018). The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. Acta Psychiatrica Scandinavica, 138(5), 420-431. https://doi.org/10.1111/acps.12952

CBE

MLA

Vancouver

Author

Østergaard, S D ; Foldager, L ; Mors, O ; Bech, P ; Correll, C U. / The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia. I: Acta Psychiatrica Scandinavica. 2018 ; Bind 138, Nr. 5. s. 420-431.

Bibtex

@article{c7625bfe2cfb4286aa074d6bc4b7f0d4,
title = "The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia",
abstract = "OBJECTIVE: To test the validity and sensitivity of the six-item version (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) in treatment-resistant schizophrenia (TRS).METHOD: Using data from the clozapine phase (2E) of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, we investigated the following: (i) The scalability of PANSS-6 and PANSS-30; (ii) The correlation between PANSS-6 and PANSS-30 total scores; (iii) Whether PANSS-6 could identify cross-sectional symptom remission; and (iv) The efficacy of clozapine, olanzapine, risperidone and quetiapine in TRS using the 'speed of change' on PANSS-6 and PANSS-30 (change in total score per week) as outcome measures.RESULTS: We found that (i) only PANSS-6 and not PANSS-30 was scalable; (ii) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), (iii) PANSS-6 accurately identified cross-sectional symptom remission as defined by the Andreasen et al. criteria; and (iv) The only antipsychotic that caused improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.50 points/week; 95{\%}CI: -0.84, -0.17) and PANSS-30 (speed of change: -1.41 points/week; 95{\%}CI: -2.80, -0.02) as outcome measures.CONCLUSION: PANSS-6 validly measures severity, remission and antipsychotic efficacy in TRS.",
author = "{\O}stergaard, {S D} and L Foldager and O Mors and P Bech and Correll, {C U}",
note = "{\circledC} 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2018",
month = "8",
day = "30",
doi = "10.1111/acps.12952",
language = "English",
volume = "138",
pages = "420--431",
journal = "Acta Psychiatrica Scandinavica",
issn = "0001-690X",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

RIS

TY - JOUR

T1 - The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia

AU - Østergaard, S D

AU - Foldager, L

AU - Mors, O

AU - Bech, P

AU - Correll, C U

N1 - © 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2018/8/30

Y1 - 2018/8/30

N2 - OBJECTIVE: To test the validity and sensitivity of the six-item version (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) in treatment-resistant schizophrenia (TRS).METHOD: Using data from the clozapine phase (2E) of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, we investigated the following: (i) The scalability of PANSS-6 and PANSS-30; (ii) The correlation between PANSS-6 and PANSS-30 total scores; (iii) Whether PANSS-6 could identify cross-sectional symptom remission; and (iv) The efficacy of clozapine, olanzapine, risperidone and quetiapine in TRS using the 'speed of change' on PANSS-6 and PANSS-30 (change in total score per week) as outcome measures.RESULTS: We found that (i) only PANSS-6 and not PANSS-30 was scalable; (ii) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), (iii) PANSS-6 accurately identified cross-sectional symptom remission as defined by the Andreasen et al. criteria; and (iv) The only antipsychotic that caused improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.50 points/week; 95%CI: -0.84, -0.17) and PANSS-30 (speed of change: -1.41 points/week; 95%CI: -2.80, -0.02) as outcome measures.CONCLUSION: PANSS-6 validly measures severity, remission and antipsychotic efficacy in TRS.

AB - OBJECTIVE: To test the validity and sensitivity of the six-item version (PANSS-6) of the 30-item Positive and Negative Syndrome Scale (PANSS-30) in treatment-resistant schizophrenia (TRS).METHOD: Using data from the clozapine phase (2E) of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study, we investigated the following: (i) The scalability of PANSS-6 and PANSS-30; (ii) The correlation between PANSS-6 and PANSS-30 total scores; (iii) Whether PANSS-6 could identify cross-sectional symptom remission; and (iv) The efficacy of clozapine, olanzapine, risperidone and quetiapine in TRS using the 'speed of change' on PANSS-6 and PANSS-30 (change in total score per week) as outcome measures.RESULTS: We found that (i) only PANSS-6 and not PANSS-30 was scalable; (ii) The correlation between PANSS-6 and PANSS-30 total scores was high (Spearman coefficient: 0.85), (iii) PANSS-6 accurately identified cross-sectional symptom remission as defined by the Andreasen et al. criteria; and (iv) The only antipsychotic that caused improvement (speed of change significantly lower than 0 during the first three months of treatment) was clozapine, both when using PANSS-6 (speed of change: -0.50 points/week; 95%CI: -0.84, -0.17) and PANSS-30 (speed of change: -1.41 points/week; 95%CI: -2.80, -0.02) as outcome measures.CONCLUSION: PANSS-6 validly measures severity, remission and antipsychotic efficacy in TRS.

U2 - 10.1111/acps.12952

DO - 10.1111/acps.12952

M3 - Journal article

VL - 138

SP - 420

EP - 431

JO - Acta Psychiatrica Scandinavica

JF - Acta Psychiatrica Scandinavica

SN - 0001-690X

IS - 5

ER -

ID: 55365294